This is a repository copy of Rhodium, Iridium, and Ruthenium Half-Sandwich Picolinamide Complexes as Anticancer Agents.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/126829/

Version: Accepted Version

Article:

https://doi.org/10.1021/ic401529u

copyright (c) 2014 American Chemical Society. This document is the Accepted Manuscript version of a Published Work that appeared in final form in Inorganic Chemistry after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/ic401529u

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Rhodium, Iridium and Ruthenium Half-Sandwich Picolinamide Complexes as Anti-Cancer Agents

Zahra Almodares, Stephanie J. Lucas, Benjamin D. Crossley, Aida M. Basri, Christopher M. Pask, Andrew J. Hebden, Roger M. Phillips and Patrick C. McGowan*

a School of Chemistry, University of Leeds, Leeds, LS2 9JT, UK
b The Institute of Cancer Therapeutics, University of Bradford, West Yorkshire, BD7 1DP, UK

Novel rhodium, iridium and ruthenium half-sandwich complexes containing (N,N)-bound picolinamide ligands have been prepared for use as anti-cancer agents. The complexes show promising cytotoxicities, with the presence, position and number of halides having a significant effect on the corresponding IC$_{50}$ value. A ruthenium complex is more cytotoxic than cisplatin on HT-29 cells and it remains active even under hypoxic conditions making it a promising candidate for in vivo studies.

Introduction

In recent years, organometallic ruthenium complexes have been well researched as anti-cancer agents. Rhodium and iridium complexes, however, remain relatively unexplored. We have previously reported an initial study demonstrating that half-sandwich ruthenium-arene picolinamide and quinaldynamide complexes with an ancillary chloride ligand show promising activity as anti-cancer agents, whereby the more hydrophobic quinaldynamide complexes are more active than their picolinamide analogues. In collaboration with Sadler, we have also shown that osmium congeners have also shown potential as cytotoxic agents. More recently, we reported a preliminary investigation into two iridium-Cp$^*$ chloride
picolinamide complexes and their IC50 values for both HT-29 and MCF-7 cell lines. In our continued study to optimise the design and potency of organometallic anti-cancer agents, we have extended our range of neutral complexes to include halide substituents on the phenyl ring for ruthenium \textit{para-cymene} and rhodium-/iridium-Cp* in order to determine structure activity relationships. It is known that cancerous cells are in a hypoxic environment whereby the median oxygen partial pressure is approximately 10 mm Hg. Many cytotoxic drugs are significantly less active when tested \textit{in vitro} on cells in a hypoxic environment compared to normoxic conditions. This is thought to be independent of the cell pathway of the drug and rather due to hypoxia-induced resistance. For this reason, the most active compound of the series under normoxic conditions has been tested on MCF-7 cells in hypoxic conditions.

**Results and Discussion**

**Synthesis of Compounds**

\textbf{Scheme 1} shows the synthesis of the group 9 complexes 1-12. The group 9 picolinamide complexes, 1-8, were prepared using various methods depending on their identity. The iridium Cp* complexes, shown in \textbf{Scheme 1a}), were prepared either according to Method A in the cases of 1, 6 and 7 or Method B in the cases of 2-5. Complex 8 was prepared according to \textbf{Scheme 1b}). The ruthenium-\textit{para}-cymene picolinamide complexes, 9-12, and quinaldamide complex, 13, were prepared according to \textbf{Scheme 1c}) and \textbf{Scheme 1d}) respectively. In all cases the picolinamide/ quinaldamide ligand was deprotonated and bound through the nitrogen atoms to form a neutral 18 electron species. All complexes were characterized by $^1$H NMR/$^{13}$C{$^1$H} NMR spectroscopy, CHN analysis and mass spectrometry. In addition, crystal structures were obtained of compounds 3, 4 and 9-13.
Scheme 1 Synthesis of a) iridium-Cp*, b) rhodium-Cp*, c) ruthenium-para-cymene picolinamide complexes and d) a ruthenium-para-cymene quinaldalamide complex

X-ray Crystallographic Data

Figure 1 shows the molecular structures of compounds 3, 4 and 9-13, with the general X-ray data shown in Table 1 and selected bond lengths and angles shown in Table 2 and Table 3 respectively. The iridium
picolinamide complexes 3 and 4 were crystallized using layer diffusion with a dichloromethane/ hexane solvent system. The ruthenium picolinamide and quinaldamide complexes, 9 and 12 respectively, were recrystallised from a methanolic solution, complexes 11 and 12 from a deuterated methanolic solution and complex 10 from an acetone solution. All of the compounds exhibit a pseudo octahedral geometry about the metal centre, whereby the para-cymene/Cp*/Cp‡ occupies 3 coordination sites and the angle between the centroid of the Cp*/Cp‡/para-cymene ring and the other coordinating atoms are between 125.9-135.1 degrees. The angle between the coordinated nitrogens and the metal centre is between 76.27 and 77.05 degrees. This is due to the rigidity of the picolinamide ligand. The angle between the nitrogens and chloride is between 81.04 and 89.59 degrees. The picolinamide ligands adopt non-planar configurations, presumably to avoid a steric clash between the ring defined as C(37)-C(42) and the arene ring. The torsion angle between the picolinamide rings ranges from 37 to 73° with no distinct trend for the varied picolinamide substituents. The Ir-centroid distances for complexes 3 and 4, within error, are the same length, with distances of 1.804 and 1.811 Å respectively. In comparison, the Ru-centroid distances are shorter than the M-centroid distances for group 9 compounds and lie in the range of 1.683-1.693 Å.
Figure 1. Molecular structures of compounds a) 3, b) 4, c) 9, d) 10, e) 11, f) 12, g) and 13. Hydrogen atoms and solvent molecules are omitted for clarity. Displacement ellipsoids are at the 50% probability level.
<table>
<thead>
<tr>
<th>Compound</th>
<th>3</th>
<th>4</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formula</td>
<td>C$<em>{23}$H$</em>{25}$Cl$_4$IrN$_2$O</td>
<td>C$<em>{22}$H$</em>{23}$Cl$_3$IrN$_2$O$_2$</td>
<td>C$<em>{44}$H$</em>{50}$Cl$_4$N$_4$O$_5$Ru$_2$</td>
<td>C$<em>{22}$H$</em>{25}$Cl$_2$N$_2$ORu</td>
<td>C$<em>{22}$H$</em>{25}$Cl$_2$N$_2$ORu</td>
<td>C$<em>{23}$H$</em>{25}$Cl$_3$N$_2$O$_2$Ru</td>
<td>C$<em>{26}$H$</em>{25}$Cl$_3$N$_2$ORu</td>
</tr>
<tr>
<td>Crystal system</td>
<td>Monoclinic</td>
<td>Monoclinic</td>
<td>Monoclinic</td>
<td>Orthorhombic</td>
<td>Triclinic</td>
<td>Orthorhombic</td>
<td>Monoclinic</td>
</tr>
<tr>
<td>Space Group</td>
<td>P2$_1$/n</td>
<td>P2$_1$/n</td>
<td>P2$_1$/n</td>
<td>Pca$_2_1$</td>
<td>P</td>
<td>P</td>
<td>P2$_1$/c</td>
</tr>
<tr>
<td>a, Å</td>
<td>7.7924(10)</td>
<td>9.7097(9)</td>
<td>17.8200(4)</td>
<td>16.1177(10)</td>
<td>8.3556(7)</td>
<td>8.5250(6)</td>
<td>8.4336(2)</td>
</tr>
<tr>
<td>b, Å</td>
<td>22.664(3)</td>
<td>14.6340(15)</td>
<td>10.5378(2)</td>
<td>8.5924(5)</td>
<td>8.3782(8)</td>
<td>13.3830(12)</td>
<td>14.5042(3)</td>
</tr>
<tr>
<td>$\alpha$, deg</td>
<td>90</td>
<td>90</td>
<td>90.00</td>
<td>90.00</td>
<td>91.676(4)</td>
<td>90.00</td>
<td>90.00</td>
</tr>
<tr>
<td>$\beta$, deg</td>
<td>97.996(6)</td>
<td>96.546(4)</td>
<td>102.2500(10)</td>
<td>90.00</td>
<td>91.676(4)</td>
<td>90.00</td>
<td>90.00</td>
</tr>
<tr>
<td>$\gamma$, deg</td>
<td>90</td>
<td>90</td>
<td>90.00</td>
<td>90.00</td>
<td>99.021(4)</td>
<td>91.2760(10)</td>
<td>90.00</td>
</tr>
<tr>
<td>V, Å$^3$</td>
<td>2555.7(6)</td>
<td>2310.4(4)</td>
<td>4442.84(17)</td>
<td>4045.4(4)</td>
<td>1085.71(17)</td>
<td>2367.3(3)</td>
<td>2390.75(11)</td>
</tr>
<tr>
<td>Z, molecules/cell</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>8</td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Density, Mg/m$^3$</td>
<td>1.766</td>
<td>1.86</td>
<td>1.583</td>
<td>1.650</td>
<td>1.642</td>
<td>1.596</td>
<td>1.631</td>
</tr>
<tr>
<td>Absorption coefficient / mm$^{-1}$</td>
<td>5.66</td>
<td>6.147</td>
<td>0.970</td>
<td>1.055</td>
<td>1.107</td>
<td>1.024</td>
<td>1.014</td>
</tr>
<tr>
<td>$\lambda$[Mo-K$_\alpha$], Å</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.71073</td>
<td></td>
</tr>
<tr>
<td>Temp, °C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.150(2)</td>
<td></td>
</tr>
<tr>
<td>Reflections</td>
<td>90089</td>
<td>63960</td>
<td>41538</td>
<td>19466</td>
<td>52845</td>
<td>59908</td>
<td>48568</td>
</tr>
<tr>
<td>Collected</td>
<td>10785</td>
<td>6880</td>
<td>10185</td>
<td>8230</td>
<td>6471</td>
<td>5810</td>
<td>5471</td>
</tr>
<tr>
<td>Independent</td>
<td>8163</td>
<td>5864</td>
<td>8799</td>
<td>7732</td>
<td>6057</td>
<td>5517</td>
<td>4940</td>
</tr>
<tr>
<td>Reflecions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R1</td>
<td>0.0235</td>
<td>0.022</td>
<td>0.0284</td>
<td>0.0314</td>
<td>0.0194</td>
<td>0.0213</td>
<td>0.0213</td>
</tr>
<tr>
<td>wR2</td>
<td>0.0346</td>
<td>0.0444</td>
<td>0.0785</td>
<td>0.0800</td>
<td>0.0504</td>
<td>0.0450</td>
<td>0.0553</td>
</tr>
<tr>
<td>GOF</td>
<td>1.096</td>
<td>1.067</td>
<td>1.053</td>
<td>1.069</td>
<td>1.058</td>
<td>1.041</td>
<td>1.091</td>
</tr>
</tbody>
</table>

**Table 1** Summary of the crystallographic data for Complexes 3, 4, and 9-13
Table 2 Selected bond lengths (Å) for compounds 3, 4, and 9-13, where M = Rh or Ir

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cl(1)-M(1)-N(1)</th>
<th>Cl(1)-M(1)-N(2)</th>
<th>N(1)-M(1)-Cl(1)</th>
<th>Cg-M(1)-N(1)</th>
<th>Cg-M(1)-Cl(1)</th>
<th>Cg-M(1)-N(2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>84.62(4)</td>
<td>86.25(5)</td>
<td>76.27(6)</td>
<td>126.74(3)</td>
<td>132.09(5)</td>
<td>132.75(5)</td>
</tr>
<tr>
<td>4</td>
<td>83.26(6)</td>
<td>85.75(7)</td>
<td>76.28(8)</td>
<td>125.93(4)</td>
<td>132.99(7)</td>
<td>133.95(7)</td>
</tr>
<tr>
<td>9</td>
<td>84.31(5)</td>
<td>86.12(5)</td>
<td>76.50(8)</td>
<td>127.53(3)</td>
<td>133.71(6)</td>
<td>130.45(6)</td>
</tr>
<tr>
<td>10</td>
<td>84.40(10)</td>
<td>87.73(10)</td>
<td>76.67(13)</td>
<td>127.14(7)</td>
<td>131.88(11)</td>
<td>131.35(12)</td>
</tr>
<tr>
<td>11</td>
<td>83.12(3)</td>
<td>85.46(3)</td>
<td>76.81(7)</td>
<td>128.39(3)</td>
<td>132.19(5)</td>
<td>131.22(5)</td>
</tr>
<tr>
<td>12</td>
<td>84.11(5)</td>
<td>85.74(5)</td>
<td>76.81(7)</td>
<td>128.04(3)</td>
<td>130.94(9)</td>
<td>128.15(5)</td>
</tr>
</tbody>
</table>

Table 3 Selected bond angles (°) for compounds 3, 4, and 9-13, where M = Rh or Ir

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cl(1)-M(1)-N(1)</th>
<th>Cl(1)-M(1)-N(2)</th>
<th>N(1)-M(1)-Cl(1)</th>
<th>Cg-M(1)-N(1)</th>
<th>Cg-M(1)-Cl(1)</th>
<th>Cg-M(1)-N(2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>84.62(4)</td>
<td>86.25(5)</td>
<td>76.27(6)</td>
<td>126.74(3)</td>
<td>132.09(5)</td>
<td>132.75(5)</td>
</tr>
<tr>
<td>4</td>
<td>83.26(6)</td>
<td>85.75(7)</td>
<td>76.28(8)</td>
<td>125.93(4)</td>
<td>132.99(7)</td>
<td>133.95(7)</td>
</tr>
<tr>
<td>9</td>
<td>84.31(5)</td>
<td>86.12(5)</td>
<td>76.50(8)</td>
<td>127.53(3)</td>
<td>133.71(6)</td>
<td>130.45(6)</td>
</tr>
<tr>
<td>10</td>
<td>84.40(10)</td>
<td>87.73(10)</td>
<td>76.67(13)</td>
<td>127.14(7)</td>
<td>131.88(11)</td>
<td>131.35(12)</td>
</tr>
<tr>
<td>11</td>
<td>83.12(3)</td>
<td>85.46(3)</td>
<td>76.81(7)</td>
<td>128.39(3)</td>
<td>132.19(5)</td>
<td>131.22(5)</td>
</tr>
<tr>
<td>12</td>
<td>84.11(5)</td>
<td>85.74(5)</td>
<td>76.81(7)</td>
<td>128.04(3)</td>
<td>130.94(9)</td>
<td>128.15(5)</td>
</tr>
</tbody>
</table>

Table 4 IC\textsubscript{50} values for complexes 1-13 on various cell lines. The cytotoxicities of the group 9 picolinamide complexes, 1-8, were tested on A2780 cells over a 5 day exposure, along with cisplatin and their respective dimeric starting materials [MCp*Cl\textsubscript{2}]\textsubscript{2}, where M = Ir, Rh, for reference. The cytotoxicities of the ruthenium compounds, 9-13, were tested on both HT-29 and MCF-7 cells over a 5 day exposure along with a further 1 hour exposure for the MCF-7 cells.

<table>
<thead>
<tr>
<th>Compound</th>
<th>A2780 IC\textsubscript{50}/μM\textsuperscript{a}</th>
<th>Compound</th>
<th>HT-29 IC\textsubscript{50}/μM\textsuperscript{a}</th>
<th>MCF-7 IC\textsubscript{50}/μM\textsuperscript{a}</th>
<th>MCF-7 IC\textsubscript{50}/μM\textsuperscript{b}</th>
</tr>
</thead>
<tbody>
<tr>
<td>cisplatin</td>
<td>0.93 ± 0.04\textsuperscript{d}/1.4 ± 0.3\textsuperscript{d}/1.5 ± 0.1\textsuperscript{e}/0.97 ± 0.07\textsuperscript{f}</td>
<td>cisplatin</td>
<td>10 ± 3</td>
<td>3 ± 1</td>
<td>53 ± 8</td>
</tr>
<tr>
<td>[IrCp*Cl\textsubscript{2}]\textsubscript{2}\textsuperscript{c}</td>
<td>30.9 ± 0.4</td>
<td>9</td>
<td>33 ± 7</td>
<td>35 ± 14</td>
<td>184 ± 2</td>
</tr>
<tr>
<td>[RhCp*Cl\textsubscript{2}]\textsubscript{2}\textsuperscript{c}</td>
<td>95 ± 2</td>
<td>10</td>
<td>13 ± 3</td>
<td>11.2 ± 0.7</td>
<td>-</td>
</tr>
<tr>
<td>1\textsuperscript{d}</td>
<td>66 ± 2</td>
<td>11</td>
<td>16 ± 3</td>
<td>11.5 ± 0.9</td>
<td>64 ± 17</td>
</tr>
<tr>
<td>2\textsuperscript{d}</td>
<td>25 ± 3</td>
<td>12</td>
<td>5.9 ± 0.8</td>
<td>5 ± 1</td>
<td>32 ± 15</td>
</tr>
<tr>
<td>3\textsuperscript{d}</td>
<td>33 ± 1</td>
<td>12 (0.5% O\textsubscript{2})</td>
<td>-</td>
<td>-</td>
<td>34 ± 5</td>
</tr>
<tr>
<td>4\textsuperscript{d}</td>
<td>18.6 ± 0.4</td>
<td>13</td>
<td>11.5 ± 0.7</td>
<td>13 ± 3</td>
<td>-</td>
</tr>
<tr>
<td>5\textsuperscript{d}</td>
<td>23 ± 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6\textsuperscript{e}</td>
<td>19.7 ± 0.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7\textsuperscript{e}</td>
<td>27 ± 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8\textsuperscript{d}</td>
<td>28.8 ± 0.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4 IC\textsubscript{50} values for complexes 1-8 on A2780 cells (with cisplatin and their respective starting dimers: [IrCp*Cl\textsubscript{2}]\textsubscript{2} and [RhCp*Cl\textsubscript{2}]\textsubscript{2} and complexes 9-13 on HT-29 and MCF-7 cells.\textsuperscript{a}The drugs were incubated
for 5 days. The drugs were incubated for an hour. \(^c,d,e\) and \(^f\) refer to different sets of A2780 cells, with different IC\(_{50}\) values for cisplatin.

For the group 9 compounds, 1-8, the presence and position of the halide substituents on the picolinamide ligand has a significant effect on the complex’s anti-cancer activity for A2780 cells. The unsubstituted IrCp* complex, 1, shows poor activity with an IC\(_{50}\) value of 66 \(\mu\)M, whereas the addition of a chloride group on the ortho and meta position of the arene ring of the picolinamide decreases the IC\(_{50}\) value to 25 and 33 \(\mu\)M respectively. The dichloro substituted picolinamide complexes show even higher activity with IC\(_{50}\) values of 19 and 23 \(\mu\)M for compounds 6 and 7 respectively. As shown in both the mono and di chloro substituted picolinamide complexes, a chloride on the ortho position of the arene ring gives a more active complex than one on the meta position. This trend is also seen with the di fluoro substituted picolinamide complexes, 6 and 7, however they are less active than the chloro analogues. The rhodium complex 8 is slightly more active than its iridium analogue, 3, with an IC\(_{50}\) value of 28 \(\mu\)M compared to 33 \(\mu\)M.

The ruthenium picolinamide complexes, 9-12, show a different trend to their iridium-Cp* analogues whereby the cytotoxicities are in the order 12>10>11>9 (where the phenyl ring substituents are 2,5-diCl, 3-Cl, 2,4-diCl and 2-Cl respectively) for all cell lines. The quinaldiamide complex 13 has similar activity to the picolinamide complex 10. Compound 12 is the most cytotoxic compound of the series, by an order of magnitude, for both cell lines after a five day exposure, particularly for HT-29 cells with higher activity than cisplatin (IC\(_{50}\) value of 6 \(\mu\)M compared to 10 \(\mu\)M). As expected, all compounds display lower activity towards MCF-7 cells after a one hour exposure compared to 5 days. Compound 12 is still the most active and, unlike the five day exposure of the same cell line, is more cytotoxic than cisplatin with an IC\(_{50}\) of 32 \(\mu\)M compared to 53 \(\mu\)M. This implies that compound 12 is a more potent drug than cisplatin. Due to this promising result, compound 12 was retested on MCF-7 cells in a hypoxic environment for a one hour exposure and it maintained its activity with an IC\(_{50}\) of 34 \(\mu\)M. This suggests that unlike cisplatin and many other cytotoxic drugs, which are reported to have reduced cytotoxic activity in a hypoxic environment \(^{22}\), compound 12 retains its activity against hypoxic cells and is not
adversely affected by hypoxia. Compound 12 has the potential to eradicate both the aerobic and hypoxic fraction of tumour cells and it is therefore a promising candidate for in vivo applications.

**Conclusions**

Various Ru-para-cymene and Rh-/Ir-Cp* or functionalised Cp* complexes have been prepared containing (N,N)-binding picolinamide ligands and their cytotoxicities on either HT-29, MCF-7 or A2780 cells have been tested. The Ir-Cp* chloride unfunctionalised picolinamide complex, 1, shows modest activity which, upon addition of a chloride, improves by 2 fold. The dihalide substituted picolinamide complexes are even more potent with the 2,4 dichloro substituent showing the highest activity with an IC\textsubscript{50} value of 18.6 µM. The Rh-Cp* 3-chloro picolinamide complex, 8, is slightly more active than its iridium analogue 5. Ruthenium-para-cymene analogues 10-13 display promising cytotoxicities on HT-29 and MCF-7 cells whereby the most active compound, 12, is more active than cisplatin for HT-29 cells and MCF-7 cells after a five day and one hour exposure respectively as well as being active under hypoxic conditions for the latter. This makes compound 12 a promising candidate for further studies.

**Experimental Details**

The picolinamide ligands\textsuperscript{24} were prepared according to the literature method. All other reagents are commercially available and were used as received. \textsuperscript{1}H- and \textsuperscript{13}C-NMR spectra were recorded on Bruker DPX 300 spectrometer. Microanalyses were obtained by Mr. Ian Blakeley at the University of Leeds Microanalytical Service. X-ray data was collected by Stephanie Lucas or Andrew Hebden. A suitable single crystal was selected and immersed in an inert oil. The crystal was then mounted onto a glass capillary and attached to a goniometer head on a Bruker X8 Apex diffractor using graphite monochromated Mo-K\textalpha\ radiation (\lambda = 0.71073 Å) and 1.0° φ-rotation frames. The crystal was then cooled to 150K by an Oxford cryostream low temperature device\textsuperscript{25} The full data set was recorded and the images processed using DENZO and SCALEPACK programs\textsuperscript{26}. The
structures were solved by Stephanie Lucas or Christopher Pask. Structure solution by direct methods was achieved through the use of SHELXS86, SIR92 or SIR97 programs, and the structural model defined by full matrix least squares on F² using SHELX97. Molecular graphics were plotted using ORTEP. Editing of Crystallographic Information files and construction of tables of bond lengths and angles was achieved using WC30 and PLATON. Hydrogen atoms were placed using idealised geometric positions (with free rotation for methyl groups), allowed to move in a “riding model” along with the atoms to which they were attached, and refined isotropically.

Cell Line Testing
The in vitro tests were performed on HT-29 (human colon adenocarcinoma), A2780 (human ovarian carcinoma) and MCF-7 (human breast adenocarcinoma) cell lines. Cells were incubated in 96-well plates at a concentration of 2 × 10⁴ cells/ml. 200 μL of growth media (RPMI 1640 supplemented with 10% foetal calf serum, sodium pyruvate (1 mM) and L-glutamine (2 mM)) was added to each well and the plates were incubated for 24 hours at 37 °C in an atmosphere of 5% CO₂ prior to drug exposure. Compounds 1-12, [IrCp*Cl₂]₂, [RhCp*Cl₂]₂ and cisplatin were all dissolved in dimethylsulphoxide at a concentration of 25 mM and diluted further with medium to obtain drug solutions ranging from 250 to 0.49 μM. The final dimethylsulphoxide concentration was 0.1% (v/v), which is non-toxic to cells. Drug solutions were applied to cells and incubated for either 1 hour or 5 days at 37 °C in an atmosphere of 5% CO₂. For 1 hour exposures, cells were washed three times with Hanks Balanced Salt Solution and then incubated for 5 days in growth medium before carrying out the MTT assay. Studies conducted under hypoxic conditions (0.1% oxygen) were performed in a Whitley H35 Hypoxystation (Don Whitley Scientific, UK) using the same protocol as described above. Following drug exposure, 20 μL of MTT (5 mg/ml⁻¹) was added to each well and incubated for 3 hours at 37 °C in an atmosphere of 5% CO₂. The solutions were then removed and 150 μL of dimethylsulphoxide was added to each well to dissolve the purple formazan crystals. A Thermo Scientific Multiskan EX microplate photometer was used to measure the absorbance at 540 nm. Lanes containing medium only and cells in medium (no drug) were used as
blanks for the spectrophotometer and 100% cell survival respectively. Cell survival was determined as the absorbance of treated cells divided by the absorbance of controls and expressed as a percentage. The IC$_{50}$ values were determined from plots of % survival against drug concentration. Each experiment was repeated 3 times and a mean value obtained.

Synthesis of IrCp*Cl(C$_{12}$H$_{9}$N$_2$O), 1. Pyridine-2-carboxylic acid phenylamide (0.05 g, 0.26 mmol) was added to a stirred suspension of [Ir{η$^5$-C$_5$(CH$_3$)$_5$}Cl$_2$)$_2$ (0.10 g, 0.13 mmol) in ethanol (30 ml) at 80 °C. After 15 minutes Ammonium hexafluorophosphate (0.10 g, 0.61 mmol) was added and the mixture was stirred at 80 °C for 20 hours. The solvent was evaporated and the residue dissolved in dichloromethane (50 ml), washed with water (2 × 20 ml), brine (20 ml), dried over sodium sulfate and evaporated to form an orange solid. The crude product was recrystallised using vapour diffusion (dichloromethane/pentane solvent system) to give 1 as orange crystals (0.06 g, 0.11 mmol, 46 %). ES-MS (CH$_2$Cl$_2$, m/z): 525.2 [M-Cl]. Anal. Found: C: 46.5, H: 4.5, N: 4.8, Cl: 6.7%. Anal. Calculated (with 0.05 molecules of dichloromethane): C: 46.9, H: 4.3, N: 5.0, Cl: 6.9%.

$^1$H NMR (300 MHz, CDCl$_3$, 300 K) 8.57 (br. d, $^3$J ($^1$H-$^1$H) = 5.4 Hz, 1H, pyridyl CH ortho to N), 8.17 (br. d, $^3$J ($^1$H-$^1$H) = 8.0 Hz, 1H, pyridyl CH meta to N, ortho to amide), 7.92 (vtd (ddd), $^3$J ($^1$H-$^1$H) = 7.7 Hz, $^3$J ($^1$H-$^1$H) = 7.7 Hz, $^4$J ($^1$H-$1^H$) = 1.4 Hz, 1H, pyridyl CH para to N), 7.65 (br. dd, $^3$J ($^1$H-$1^H$) = 8.3 Hz, $^4$J ($^1$H-$^1$H) = 1.1 Hz, 2H, 2 × phenyl CH ortho to amide), 7.49 (ddd, $^3$J ($^1$H-$1^H$) = 7.5 Hz, $^3$J ($^1$H-$^1$H) = 5.6 Hz, $^4$J ($^1$H-$1^H$) = 1.7 Hz, 1H, pyridyl CH para to amide), 7.32 (m, 2H, 2 × phenyl CH meta to amide), 7.09 (t, $^3$J ($^1$H-$^1$H) = 7.3 Hz, ) 1H, phenyl CH para to amide), 7.41 (s, 15H, 5 × CH$_3$). $^{13}$C{ $^1$H} NMR (75 MHz, CD$_2$Cl$_2$, 300 K) 168.4 (NCO), 155.8 (CCON) 149.5 (CH ortho to N on pyridyl ring), 148.1 (CCON), 138.5 (CH para to N on pyridyl ring), 128.1 (CH meta to NCOR), 127.3 (CH para to CO on pyridyl ring) 126.9 (CH ortho to NCOR), 126.5 (CH ortho to CON on pyridyl ring), 124.3 (CH para to NCO), 86.5 (CCCH$_3$), 8.4 (CCCH$_3$).

Synthesis of IrCp*Cl(C$_{12}$H$_8$ClN$_2$O), 2. Pyridine-2-carboxylic acid (2-chloro-phenyl) amide (0.06 g, 0.26 mmol) was added to a stirred suspension of [Ir{η$^5$-C$_5$(CH$_3$)$_5$}Cl$_2$)$_2$ (0.10 g, 0.13 mmol) and sodium
bicarbonate (0.02 g, 0.26 mmol) in methanol (3 ml) in a 10 ml capacity microwave tube. The tube was then sealed and microwave heating was applied at 150 °C for 10 minutes. After effervescence from the solution had subsided, the tube was opened and left to cool. The resulting suspension was filtered, washed with diethyl ether and dried in vacuo to yield orange crystals of 2 (0.10 g, 0.17 mmol, 65%). ES-MS (CH₂Cl₂, m/z): 559.1 [M-Cl]. Anal. Found: C: 44.2, H: 4.1, N: 4.6, Cl: 11.5%. Anal. Calculated: C: 44.4, H: 3.9, N: 4.7, Cl: 11.9%.

1H NMR (300 MHz, CDCl₃, 300 K) 8.58 (ddd, 3J (1H-1H) = 5.5 Hz, 4J (1H-1H) = 1.4 Hz, 5J (1H-1H) = 0.7 Hz, 1H, pyridyl CH ortho to N), 8.21 (ddd, 3J (1H-1H) = 7.9 Hz, 4J (1H-1H) = 1.7 Hz, 5J (1H-1H) = 0.7 Hz, 1H, pyridyl CH meta to N, ortho to amide), 7.93 (vtd (ddd), 3J (1H-1H) = 8.1 Hz, 3J (1H-1H) = 7.8 Hz, 4J (1H-1H) = 1.4 Hz, 1H, pyridyl CH meta to N, ortho to amide), 7.84 (dd, 3J (1H-1H) = 7.9 Hz, 4J (1H-1H) = 1.7 Hz, 1H, phenyl CH ortho to amide), 7.49 (vt (dd)), 3J (1H-1H) = 6.6 Hz, 3J (1H-1H) = 5.6 Hz, 4J (1H-1H) = 1.4 Hz, 1H, pyridyl CH para to amide), 7.40 (dd, 3J (1H-1H) = 7.9 Hz, 4J (1H-1H) = 1.6 Hz, 1H, phenyl CH ortho to Cl), 7.23 (masked vtd (dd)), 3J (1H-1H) = 8.1 Hz, 3J (1H-1H) = 7.6 Hz, 4J (1H-1H) = 1.4 Hz, 1H, phenyl CH para to Cl), 7.09 (dd, 3J (1H-1H) = 8.1 Hz, 3J (1H-1H) = 7.8 Hz, 4J (1H-1H) = 1.7 Hz, 1H, phenyl CH para to amide), 1.47 (s, 15H, 5 × CH₃). 13C {1H} NMR (125 MHz, CD₂Cl₂, 300 K) 168.5 (NCO), 155.2 (CON), 150.4 (CH ortho to N on pyridyl ring), 147.2 (CNCO), 139.2 (C para to N on pyridyl ring), 132.8 (CCl), 129.5 (CH ortho to Cl and meta to NCO), 128.7 (CH ortho to NCO and meta to Cl), 128.0 (CH para to CO and meta to N on pyridyl ring), 127.9 (CH para to Cl), 126.9 (CH ortho to CO and meta to N on pyridyl ring), 126.3 (CH para to NCO), 87.5 (CH₃), 9.0 (CH₃).

Synthesis of IrCp*Cl(C₃H₈ClN₆O), 3. Pyridine-2-carboxylic acid (3-chloro-phenyl) amide (0.06 g, 0.26 mmol) was added to a stirred suspension of [Ir{ś₅-C₅(CH₃)₅}Cl₂]₂ (0.10 g, 0.13 mmol) and sodium bicarbonate (0.02 g, 0.26 mmol) in methanol (3 ml) in a 10 ml capacity microwave tube. The tube was then sealed and microwave heating was applied at 150 °C for 10 minutes. After effervescence from the solution had subsided, the tube was opened and left to cool. The resulting suspension was filtered, washed with hexane and dried in vacuo to yield orange crystals of 3 (0.11 g, 0.19 mmol, 71%). ES-MS (CH₂Cl₂, m/z): 559.1 [M-Cl]. Anal. Found: C: 44.1, H: 4.3, N: 4.3, Cl: 11.5%. Anal. Calculated: C: 44.4, H: 3.9, N:
4.7, Cl: 11.9%. $^1$H NMR (300 MHz, CDCl$_3$, 300 K) 8.58 (ddd, $J$ = Hz, 1H, CH of pyridyl ortho to N), 8.16 (ddd, 1H, CH of pyridyl meta to N, ortho to CON), 7.94 (vt (ddd), 1H, CH of pyridyl para to N), 7.73 (vt (dd), 1H, CH ortho to NCO and Cl), 7.61 (ddd, 1H, CH of phenyl para to NCO), 7.50 (ddd, 1H, CH of pyridyl meta to N, para to CON), 7.24 (vt (dd), 1H, CH of phenyl meta to NCO and Cl), 7.08 (ddd, 1H, CH para to Cl), 1.43 (s, 15H, 5 × CH$_3$).

$^{13}$C{$^1$H} NMR (75 MHz, CDCl$_3$, 300 K) 168.4 (NCO), 155.4 (CCON), 149.6 (CH ortho to N on pyridyl ring), 149.4 (C para to N on pyridyl ring), 133.5 (CCl), 129.0 (CH meta to Cl and NCO), 127.5 (CH para to CO and meta to N on pyridyl ring), 127.3 (CH ortho to NCO and Cl), 126.6 (CH ortho to CO and meta to N on pyridyl ring), 125.3 (CH ortho to Cl and meta to NCO), 124.3 (CH para to Cl), 86.7 (CCH$_3$), 8.5 (CCH$_3$).

**Synthesis of IrCp*Cl(C$_{12}$H$_7$Cl$_2$N$_2$O), 4.** Pyridine-2-carboxylic acid (2,4-dichloro-phenyl) amide (0.07 g, 0.06 mmol) was added to a stirred suspension of [Ir{η$^5$-C$_5$(CH$_3$)$_5$}Cl$_2$]$_2$ (0.10 g, 0.13 mmol) and sodium bicarbonate (0.02 g, 0.26 mmol) in methanol (3 ml) in a 10 ml capacity microwave tube. The tube was then sealed and microwave heating was applied at 150 °C for 10 minutes. After effervescence from the solution had subsided, the tube was opened and left to cool. The resulting suspension was filtered, washed with ether and dried in vacuo to yield orange crystals of 4 (0.11 g, 0.17 mmol, 67 %). ES-MS (CH$_2$Cl$_2$, m/z): 593.1 [M-Cl]. Anal. Found: C: 41.6, H 3.9, N: 4.1, Cl: 16.0% Anal. Calculated (with 0.8 molecules of water): C: 41.1, H: 3.7, N: 4.4, Cl: 16.5%.

$^1$H NMR (300 MHz, CDCl$_3$, 300 K) 8.61 (br. d, $^3$J(H-H) = 5.7 Hz, 1H, pyridyl CH ortho to N), 8.24 (br. d, $^3$J(H-H) = 8.1 Hz, pyridyl CH meta to N, ortho to amide), 7.98 (vt (dd), $^3$J(H-H) = 7.6 Hz, $^4$J(H-H) = 1.4 Hz, 1H, pyridyl CH para to N), 7.86 (br. d, $^3$J(H-H) = 8.6 Hz, 1H, phenyl CH ortho to amide, meta to both Cl), 7.54 (ddd, $^3$J(H-H) = 7.5 Hz, $^3$J(H-H) = 5.7 Hz, $^4$J(H-H) = 1.4 Hz, 1H, pyridyl CH para to amide), 7.47 (d, $^4$J(H-H) = 2.4 Hz, 1H, phenyl CH ortho to both Cl), 7.25 (dd, $^3$J(H-H) = 8.6 Hz, $^4$J(H-H) = 2.4 Hz, 1H, phenyl CH meta to amide, ortho and para to Cl), 1.49 (s, 15H, 5 × CH$_3$). $^{13}$C{$^1$H} NMR (125 MHz, CD$_2$Cl$_2$, 300 K) 168.6 (NCO), 154.9 (CCON), 150.5 (CH ortho to N on pyridyl ring), 146.1 (CNO), 139.3 (C para to N on pyridyl ring), 133.6 (CCl ortho to NCO), 130.7 (CCl para to NCO) 129.7 (CH ortho to NCO and meta to...
both Cl), 129.2 (CH meta to NCO and ortho to both Cls), 128.2 (CH para to CO and meta to N on pyridyl ring), 127.0 (CH ortho to CO and meta to N on pyridyl ring), 87.6 (5 × CCH$_3$), 9.1 (5 × CCH$_3$).

**Synthesis of IrCp*Cl(C$_{12}$H$_7$Cl$_2$N$_2$O), 5.** Pyridine-2-carboxylic acid (2,5-dichloro-phenyl) amide (0.07 g, 0.26 mmol) was added to a stirred suspension of [Ir(η$^5$-C$_5$(CH$_3$)$_5$)Cl$_2$]$_2$ (0.10 g, 0.13 mmol) and sodium bicarbonate (0.02 g, 0.26 mmol) in methanol (3 ml) in a 10 ml capacity microwave tube. The tube was then sealed and microwave heating was applied at 150 °C for 10 minutes. After effervescence from the solution had subsided, the tube was opened and left to cool. The resulting suspension was filtered, washed with ether and dried in vacuo to yield 5 as a yellow powder (0.13 g, 0.21 mmol, 82 %). ES-MS (CH$_2$Cl$_2$, m/z): 593.1 [M-Cl]. Anal. Found: C: 41.5, H: 3.4, N: 4.2, Cl: 16.6%. Anal. Calculated: C: 42.0, H: 3.5, N, 4.5, Cl: 16.9%. $^1$H NMR (300 MHz, CDCl$_3$, 300 K) 8.58 (ddd, 3$^J$ (1H-1H) = 5.6 Hz, 4$^J$ (1H-1H) = 1.4 Hz, 5$^J$ (1H-1H) = 0.6 Hz, 1H, pyridyl CH ortho to N), 8.22 (ddd, 3$^J$ (1H-1H) = 7.8 Hz, 4$^J$ (1H-1H) = 1.6 Hz, 5$^J$ (1H-1H) = 0.6 Hz, 1H, pyridyl CH meta to N, ortho to amide), 7.95 (vtd, 3$^J$ (1H-1H) = 7.7 Hz, 3$^J$ (1H-1H) = 7.7 Hz, 4$^J$ (1H-1H) = 1.4 Hz, 1H, pyridyl CH para to N), 7.89 (br. d, 4$^J$ (1H-1H) = 2.6 Hz, 1H, CH ortho to Cl and NCOR), 7.50 (ddd, 3$^J$ (1H-1H) = 6.5 Hz, 3$^J$ (1H-1H) = 5.6 Hz, 4$^J$ (1H-1H) = 1.7 Hz, 1H, pyridyl CH para to amide), 7.33 (br. d, 3$^J$ (1H-1H) = 8.5 Hz, 1H, CH meta to NCOR) 7.07 (dd, 3$^J$ (1H-1H) = 8.6 Hz, 4$^J$ (1H-1H) = 2.6 Hz, 1H, CH para to NCOR), 1.49 (s, 15H, CCH$_3$). $^{13}$C {$^1$H} NMR (75 MHz, CDCl$_3$, 300 K) 167.8 (NCO), 154.5 (CCON), 149.5 (CH ortho to N on pyridyl ring), 147.3 (CNCO), 138.7 (C para to N on pyridyl ring), 132.6 (CCl meta to NCO), 130.8 (CCl ortho to NCO) 129.8 (CH meta to NCOR), 128.5 (CH ortho to NCOR), 127.5 (CH para to CO and meta to N on pyridyl ring), 127.0 (CH ortho to CONR), 125.8 (CH para to NCOR), 87.0 (5 × CCH$_3$), 8.7 (5 × CCH$_3$).

**Synthesis of IrCp*Cl(C$_{12}$H$_7$F$_2$N$_2$O), 6.** Pyridine-2-carboxylic acid (2,4-difluoro-phenyl) amide (0.07 g, 0.30 mmol) and [IrCp*Cl$_2$]$_2$ (0.10 g, 0.13 mmol) were dissolved in ethanol (30 ml) and the solution was refluxed for 30 minutes. Ammonium hexafluorophosphate (0.10g, 0.61 mmol) was added and the mixture was refluxed overnight. The resulting yellow solution was evaporated to dryness, redissolved in
dichloromethane (50 ml) and washed with water (2 × 10 ml) & brine (10 ml), dried using sodium sulfate and filtered. 6 was recrystallised by dichloromethane/hexane layer diffusion (0.06 g, 0.10 mmol, 40%).

ES-MS (CH₂Cl₂, m/z): 561.1 [M-Cl]. Anal. Found: C: 43.8, H: 3.8, N: 4.4%. Anal. Calculated: C: 44.3, H: 3.7, N: 4.7%. ¹H NMR (300 MHz, CDCl₃, 300 K) 8.58 (br. d, ³J (¹H-¹H) = 5.6 Hz, 1H, pyridyl CH ortho to N), 8.18 (br. d, ³J (¹H-¹H) = 7.5 Hz, 1H, pyridyl CH meta to N, ortho to amide), 7.94 (vdt (ddd), ³J (¹H-¹H) = 7.8 Hz, ³J (¹H-¹H) = 7.5 Hz, ⁴J (¹H-¹H) = 1.4 Hz, 1H, pyridyl CH para to N), 7.75 (vbr. q (ddd), ³J (¹H-¹H) =  8.6 Hz, ³J (¹H-¹H) =  8.6 Hz, ⁴J (¹H-¹F) =  8.6 Hz, 1H, phenyl CH ortho to NCO and F), 7.51 (ddd, ³J (¹H-¹H) = 7.3 Hz, ³J (¹H-¹H) = 5.8 Hz, ⁴J (¹H-¹H) = 1.7 Hz, 1H, pyridyl CH para to amide), 6.86 (m, 2H, CH ortho to F groups and CH ortho and para to F), 1.45 (s, 15H, 5 × CH₃). ¹³C {¹H} NMR (125 MHz, CDCl₃, 300 K) 168.4 (NCO), 159.9 (dd, ²J (¹³C-¹⁹F) = 245.1 Hz , ⁴J (¹³C-¹⁹F) = 11.1 Hz, CF), 157.6 (dd, ²J (¹³C-¹⁹F) = 294.4 Hz , ⁴J (¹³C-¹⁹F) = 11.8 Hz, CF), 154.4 (CCON), 149.6 (CH ortho to N on pyridyl ring), 138.6 (CH para to N on pyridyl ring), 132.2 (dd, ²J (¹³C-¹⁹F) =13.2 Hz , ⁴J (¹³C-¹⁹F) = 3.9 Hz, C=CON), 128.8 (dd, ³J (¹³C-¹⁹F) = 9.3 Hz , ³J (¹³C-¹⁹F) =  4.1 Hz, CH ortho to NCO), 127.5 (CH para to CONR), 126.7 (CH ortho to CO and meta to N on pyridyl ring), 111.0 (dd, ²J (¹³C-¹⁹F) =21.5 Hz , ⁴J (¹³C-¹⁹F) = 3.5 Hz, CH meta to NCO and para to F), 103.4 (vt (dd), ²J (¹³C-¹⁹F)=25.5 Hz , ²J (¹³C-¹⁹F) =25.5 Hz, CH ortho to F groups), 86.6 (5 × CCH₃), 8.4 (5 × CCH₃).

**Synthesis of IrCp*Cl(C₁₂H₇F₂N₂O).** 7. Pyridine-2-carboxylic acid (2,5-difluoro-phenyl) amide (0.07 g, 0.30 mmol) and [IrCp*Cl₂]₂ (0.10 g, 0.13 mmol) were dissolved in ethanol (30 ml) and the solution was refluxed for 30 mins. Ammonium hexafluorophosphate (0.10 g, 0.61 mmol) was added and the mixture was refluxed overnight. The resulting yellow solution was evaporated to dryness, redissolved in dichloromethane (50 ml) and washed with water (2 × 10 ml) & brine (10 ml), dried using sodium sulfate and filtered. 7 was recrystallised by dichloromethane/hexane layer diffusion (0.07 g, 0.12 mmol, 47%).

ES-MS (CH₂Cl₂, m/z): 561.1 [M-Cl]. Anal. Found: C: 44.5, H: 3.7, N: 4.6%. Anal. Calculated: C: 44.3, H: 3.7, N: 4.7%. ¹H NMR (300 MHz, CDCl₃, 300 K) 8.59 (br. d, ³J (¹H-¹H) = 5.5 Hz, ³J (¹H-¹H) = 1.4 Hz, ³J (¹H-¹H) = 0.7 Hz, 1H, pyridyl CH ortho to N), 8.19 (ddd, ³J (¹H-¹H) = 7.8 Hz, ⁴J (¹H-¹H) = 1.6 Hz, ⁵J
(1H-1H) = 0.7 Hz, 1H, pyridyl CH meta to N, ortho to amide), 7.95 (vdt (ddd), 3J (1H-1H) = 7.7 Hz, 3J (1H-1H) = 7.7 Hz, 4J (1H-1H) = 7.7 Hz, 1H, pyridyl CH para to N), 7.48-7.58 (m, 2H, pyridyl CH para to amide and phenyl CH ortho to NCO and F), 7.07 (vtd (ddd), 3J (1H-1H) = 5.1 Hz, 3J (1H-1H) = 9.2 Hz, 4J (1H-1H) = 9.2 Hz, 1H, phenyl CH meta to amide), 6.77 - 6.85 (m, 1H, phenyl CH para to NCO) 1.46 (s, 15H, 5 × CH3). 13C (1H) NMR (125 MHz, CDCl3, 300 K) 168.2 (NCO), 159.8 (dd, 1J (13C-19F) = 242.5 Hz, 4J (13C-19F) = 2.3 Hz, CF meta to NCO), 153.4 (dd, 1J (15C-19F) = 242.4 Hz, 4J (13C-19F) = 2.9 Hz, CF ortho to NCO), 154.4 (CCON), 149.6 (CH ortho to N on pyridyl ring), 138.7 (CH para to N on pyridyl ring), 137.1 (dd, 2J (13C-19F) = 15.7 Hz, 3J (13C-19F) = 11.3 Hz, CCON), 127.6 (CH para to CONR), 126.8 (CH ortho to CO and meta to N on pyridyl ring), 115.7 (dd, 2J (19F-13C) = 23.9 Hz, 3J (19F-13C) = 9.7 Hz, CH meta to NCO), 114.9 (dd, 2J (19F-13C) = 24.7 Hz, 3J (19F-13C) = 2.9 Hz, CH ortho to NCO) 112.1(dd, 2J (19F-13C) = 24.3 Hz, 3J (19F-13C) = 7.9 Hz, CH para to NCO), 86.7 (5 × CCH3), 8.4 (5 × CCH3).

Synthesis of RhCp*Cl(C12H3ClN2O). 8. Pyridine-2-carboxylic acid (3-chloro-phenyl) amide (0.06 g, 0.26 mmol) and sodium bicarbonate (0.02 g, 0.26 mmol) was added to a stirred suspension of [RhCp*Cl]2 (0.12 g, 0.13 mmol) in methanol (25 ml). The mixture was heated to reflux for 18 hours. The resulting solution was evaporated to dryness and the crude product recrystallised from hot methanol to give red crystals of 8 suitable for X-ray crystallography. The bulk sample was purified using layer diffusion with a dichloromethane/hexane solvent system (0.15 g, 0.30 mmol, 76 %). ES-MS (CH3Cl, m/z): 469.1 [M-Cl].

Anal. Found: C: 50.8, H: 4.9, N: 4.9%. Anal. Calculated (with 0.33 molecules of dichloromethane): C: 50.3, H: 4.5, N: 5.3%. 1H NMR (300 MHz, CDCl3, 300 K) 8.63 (br. d, J (1H-1H) = 5.4 Hz, 1H, CH of pyridyl ortho to N), 8.16 (br. d, J (1H-1H) = 7.8 Hz, 1H, CH of pyridyl meta to N, ortho to CON), 7.95 (vtd (ddd), 3J (1H-1H) = 7.7 Hz, 3J (1H-1H) = 7.7 Hz, 4J (1H-1H) = 1.4 Hz, 1H, CH of pyridyl para to N), 7.83 (vt (dd), 4J (1H-1H) = 2.0 Hz, 1H, CH ortho to NCO and Cl), 7.72 (ddd, 3J (1H-1H) = 8.0 Hz, 4J (1H-1H) = 1.8 Hz, 4J (1H-1H) = 1.0 Hz, 1H, CH of phenyl para to NCO), 7.54 (ddd, 3J (1H-1H) = 6.5 Hz, 3J (1H-1H) = 5.6 Hz, 4J (1H-1H) = 1.6 Hz, 1H, CH of pyridyl meta to N, para to CON), 7.24 (masked vt (dd), 3J (1H-1H) = 8.0 Hz, 1H, CH of phenyl meta to NCO and Cl), 7.06 (ddd, 1H, 3J (1H-1H) = 8.0 Hz, 4J
$^{1}H$-$^{1}H$ = 2.1 Hz, $^{4}J(^{1}H$-$^{1}H$) = 1.1 Hz, CH para to Cl, 1.43 (s, 15H, 5 × CH$_{3}$). $^{13}$C $^{1}H$ NMR (75 MHz, CDCl$_{3}$, 300 K) 168.6 (NCO), 156.3 (CCON), 149.7 (CH ortho to N on pyridyl ring), 149.6 (CNCO), 138.9 (C para to N on pyridyl ring), 133.5 (CCl), 128.9 (CH meta to Cl and NCO), 127.4 (CH para to CO and meta to N on pyridyl ring), 127.1 (CH ortho to NCO and Cl), 126.1 (CH ortho to CO and meta to N on pyridyl ring), 125.5 (CH ortho to Cl and meta to NCO), 124.0 (CH para to Cl), 94.7 (d, $^{1}J^{13}$C-$^{103}$Rh) = 8.0 Hz, CCH$_{3}$), 8.6 (CCH$_{3}$).

**Synthesis of Ru-para-cymene Cl(C$_{12}$H$_{8}$ClN$_{2}$O)**, 9. Pyridine-2-carboxylic acid (2-chloro-phenyl) amide (0.07 g, 0.32 mmol) was added to a solution of [Ru{η$^{6}$-para-cymene}Cl$_{2}$]$_{2}$ (0.10 g, 0.16 mmol) in ethanol (50 ml) and the mixture was warmed at 50 °C for 15 minutes then filtered over to ammonium hexafluorophosphate (0.10 g, 0.61 mmol). The resulting solution was stirred overnight then evaporated to dryness. The crude product was washed with petroleum ether (bp 40-60 °C) (3 × 10 ml) and recrystallised from methanol to yield orange crystals of 9 (0.076 g, 0.15 mmol, 47%). ES MS (+): m/z 503 [M$^{+}$]. Anal. Found: C 50.20; H 4.55; N 5.30%. Anal. Calculated (with 1 molecule of H$_{2}$O): C 50.77; H 4.65; N 5.38%.

$^{1}$H NMR (CD$_{3}$OD, γ00.1γMHz, γ00K) į λ.γγ (d, 1H, $^{3}J(^{1}$H-$^{1}$H)= 5.4 Hz, CH of C$_{5}$H$_{4}$N), 8.12 (t of d, 1H, $^{3}J(^{1}$H-$^{1}$H)= 7.8 Hz, $^{4}J(^{1}$H-$^{1}$H)= 1.5 Hz, CH of C$_{5}$H$_{4}$N), 7.96 (d of d, 1H, $^{3}J(^{1}$H-$^{1}$H)= 7.8 Hz, $^{4}J(^{1}$H-$^{1}$H)= 1.5 Hz, CH of C$_{5}$H$_{4}$N), 7.76 (d of d, 1H, $^{3}J(^{1}$H-$^{1}$H)= 7.8 Hz, $^{4}J(^{1}$H-$^{1}$H)= 1.5 Hz, CH of C$_{6}$H$_{4}$Cl), 7.69 (m, 1H, CH of C$_{5}$H$_{4}$N), 7.57 (d of d, 1H, $^{3}J(^{1}$H-$^{1}$H)= 7.9 Hz, $^{4}J(^{1}$H-$^{1}$H)= 1.6 Hz, CH of C$_{6}$H$_{4}$Cl), 7.25-7.38 (m, 2H, 2 x CH of C$_{6}$H$_{4}$Cl), 5.60 (d, 1H, $^{3}J(^{1}$H-$^{1}$H)= 6.3 Hz, CH of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$, 5.44-5.53 (m, 2H, 2 x CH of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$), 4.82 (m, 1H, CH of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$, 2.69 (sept, 1H, $^{3}J(^{1}$H-$^{1}$H)= 6.9 Hz, CH of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$), 2.10 (s, 3H, CH$_{3}$ of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$), 1.10 (d, 3H, $^{3}J(^{1}$H-$^{1}$H)= 6.9 Hz, CH of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$), 1.00 (d, 3H, $^{3}J(^{1}$H-$^{1}$H)= 6.9 Hz, CH of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$), $^{13}$C $^{1}H$ NMR (CD$_{3}$OD, 75.47MHz, 300K) δ 169.0 (CONRu), 156.3 (CH of C$_{5}$H$_{4}$N), 156.2 (Quaternary C), 150.9 (Quaternary C), 140.8 (CH of C$_{5}$H$_{4}$N), 131.8 (Quaternary C), 131.1 (CH of C$_{6}$H$_{4}$Cl), 129.4 (CH of C$_{6}$H$_{4}$Cl), 129.0 (CH), 128.3 (CH of C$_{6}$H$_{4}$Cl), 126.9 (CH of C$_{5}$H$_{4}$N), 105.4 (Quaternary C of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$), 99.7 (Quaternary C of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$), 88.1 (CH of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$), 81.5 (CH of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$), 24.4 (CH of H$_{2}$CC$_{6}$H$_{4}$C(H)(CH$_{3}$)$_{2}$)
86.7 (CH of $\text{H}_2\text{C}_6\text{H}_4\text{C}(\text{H})(\text{CH}_3)_2$), 86.5 (CH of $\text{H}_2\text{C}_6\text{H}_4\text{C}(\text{H})(\text{CH}_3)_2$), 82.6 (CH of $\text{H}_2\text{C}_6\text{H}_4\text{C}(\text{H})(\text{CH}_3)_2$), 32.9 (CH of $\text{H}_2\text{CC}_6\text{H}_4\text{C}(\text{H})(\text{CH}_3)_2$), 23.4 (CH$_3$ of $\text{H}_2\text{CC}_6\text{H}_4\text{C}(\text{H})(\text{CH}_3)_2$), 22.3 (CH$_3$ of $\text{H}_2\text{CC}_6\text{H}_4\text{C}(\text{H})(\text{CH}_3)_2$), 19.1 (CH$_3$ of $\text{H}_2\text{CC}_6\text{H}_4\text{C}(\text{H})(\text{CH}_3)_2$).

**Synthesis of Ru-para-cymene Cl(C$_2$H$_5$CN$_2$O), 10.** Pyridine-2-carboxylic acid (3-chloro-phenyl) amide (0.07 g, 0.32 mmol) was added to a solution of [Ru{η$^6$-para-cymene}Cl$_2$]$_2$ (0.10 g, 0.21 mmol, 65%) in ethanol (50 ml) and the mixture was warmed at 50 °C for 15 minutes then filtered over to ammonium hexafluorophosphate (0.10 g, 0.61 mmol). The resulting solution was stirred overnight then evaporated to dryness. The crude product was washed with petroleum ether (bp 40-60 °C) (3 x 10 ml) and recrystallised from methanol to yield orange crystals of 10 (0.104 g, 0.21 mmol, 65%). ES MS (+): m/z 503 [M$^+$]. Anal. Found: C 52.2; H 4.4; N 5.5%. Anal. Calc.: C 52.6; H 4.4; N 5.6%.

$^1$H NMR (CD$_2$OD, 500.13 MHz, 300 K) δ 9.27 (br. d, 1H, $^3$J(1-H-1) = 5.5 Hz, CH of C$_6$H$_4$N), 8.09 (t of d, 1H, $^3$J(1-H-1) = 7.7 Hz, CH of C$_6$H$_4$N), 7.95 (br. d, 1H, $^3$J(1-H-1) = 7.8 Hz, CH of C$_6$H$_4$N), 7.64-7.68 (m, 2H, 2 x CH), 7.53 (m, 1H, CH of C$_6$H$_4$Cl), 7.39 (t, 1H, $^3$J(1-H-1) = 8.0 Hz, CH of C$_6$H$_4$Cl), 7.23 (m, 1H, CH of C$_6$H$_4$Cl), 5.59 (d, 1H, $^3$J(1-H-1) = 6.1 Hz, CH of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 5.42 (d, 1H, $^3$J(1-H-1) = 6.1 Hz, CH of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 5.30 (d, 1H, $^3$J(1-H-1) = 6.1 Hz, CH of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 5.28 (sept, 1H, $^3$J(1-H-1) = 6.9 Hz, CH of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 2.16 (s, 3H, CH$_3$ of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 1.05-1.30 (m, 6H, 2 x CH$_3$ of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$); $^{13}$C $^1$H NMR (CD$_2$OD, 125.77MHz, 300K) δ 169.1 (CONRu), 156.2 (Quaternary C), 155.8 (CH of C$_6$H$_4$N), 154.4 (Quaternary C), 140.8 (CH of C$_6$H$_4$N), 134.9 (Quaternary C), 130.8 (CH of C$_6$H$_4$Cl), 128.6 (CH), 127.5 (CH), 126.6 (CH of C$_6$H$_4$N), 126.0 (CH of C$_6$H$_4$Cl), 125.9 (CH of C$_6$H$_4$Cl), 103.7 (Quaternary C of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 101.9 (Quaternary C of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 86.3 (CH of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 85.9 (CH of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 85.5 (CH of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 85.3 (CH of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 32.2 (CH of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 22.5 (CH$_3$ of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 22.1 (CH$_3$ of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$), 18.9 (CH$_3$ of H$_2$CC$_6$H$_4$C(H)(CH$_3$)$_2$); ES MS (+): m/z 467 [M$^+$]-Cl.
Synthesis of Ru-para-cymene Cl(C₁₂H₂Cl₂N₂O), 11. Pyridine-2-carboxylic acid (2,4-dichloro-phenyl) amide (0.09 g, 0.32 mmol) was added to a solution of [Ru\{η⁶-para-cymene\}Cl₂]₂ (0.10 g, 0.16 mmol) in ethanol (50 ml) and the mixture was warmed at 50 °C for 15 minutes then filtered over to ammonium hexafluorophosphate (0.10 g, 0.61 mmol). The resulting solution was stirred overnight then evaporated to dryness. The crude product was washed with petroleum ether (bp 40-60 °C) (3 × 10 ml) and recrystallised from methanol to yield orange crystals of 11 (0.098 g, 0.18 mmol, 57%). ES MS (+): m/z 501 [M⁺]-Cl. Anal. Found: C 49.1; H 3.9; N 5.2%. Anal. Calc.: C 49.2; H 3.9; N 5.2%. ¹H NMR (CD₂OD, 500.13MHz, 300K) δ 9.31 (d, 1H, ³J(¹H-¹H)= 5.0 Hz, CH of C₃H₄N), 8.11 (t of d, 1H, ³J(¹H-¹H)= 7.7 Hz, ⁴J(¹H-¹H)= 1.4 Hz, CH of C₃H₄N), 7.95 (br, 1H, ¹J(¹H-¹H)= 7.8 Hz, CH of C₃H₄N), 7.75 (d, 1H, ³J(¹H-¹H)= 8.5 Hz, CH of C₆H₅Cl₂), 7.69 (m, 1H, CH of C₆H₄N), 7.60 (d, 1H, ⁴J(¹H-¹H)= 2.3 Hz, CH of C₆H₅Cl₂), 7.36 (d of d, 1H, ³J(¹H-¹H)= 8.5 Hz, ⁴J(¹H-¹H)= 2.3 Hz, CH of C₆H₅Cl₂), 5.65 (d, 1H, ³J(¹H-¹H)= 6.7 Hz, CH of H₃C₆H₅C(H)(CH₃)₂), 5.47-5.48 (m, 2H, 2 x CH of H₃C₆H₅C(H)(CH₃)₂), 4.90 (d, 1H, ³J(¹H-¹H)= 6.0 Hz, CH of H₃C₆H₅C(H)(CH₃)₂), 2.10 (s, 3H, CH₃ of H₃C₆H₅C(H)(CH₃)₂), 1.09 (d, 3H, ³J(¹H-¹H)= 6.9 Hz, CH₃ of H₃C₆H₅C(H)(CH₃)₂), 1.01 (d, 3H, ³J(¹H-¹H)= 6.9 Hz, CH₃ of H₃C₆H₅C(H)(CH₃)₂), 1.01 (d, 3H, ³J(¹H-¹H)= 6.9 Hz, CH₃ of H₃C₆H₅C(H)(CH₃)₂), 1.09 (d, 3H, ³J(¹H-¹H)= 6.9 Hz, CH₃ of H₃C₆H₅C(H)(CH₃)₂), 13C {¹H} NMR (CD₂OD, 125.77MHZ, 300K) δ 155.8 (CH of C₆H₅N), 155.6 (Quaternary C), 149.4 (Quaternary C), 140.5 (CH of C₆H₅N), 132.5 (Quaternary C), 132.2 (Quaternary C), 130.3 (CH of C₆H₅Cl₂), 130.1 (CH of C₆H₅Cl₂), 128.9 (CH of C₆H₅Cl₂), 128.7 (CH of C₆H₄N), 126.5 (CH of C₆H₄N), 105.0 (Quaternary C of H₃C₆H₅C(H)(CH₃)₂), 99.9 (Quaternary C of H₃C₆H₅C(H)(CH₃)₂), 87.2 (CH of H₃C₆H₅C(H)(CH₃)₂), 86.3 (CH of H₃C₆H₅C(H)(CH₃)₂), 85.9 (CH of H₃C₆H₅C(H)(CH₃)₂), 82.7 (CH of H₃C₆H₅C(H)(CH₃)₂), 32.3 (CH of H₃C₆H₅C(H)(CH₃)₂), 22.9 (CH₃ of H₃C₆H₅C(H)(CH₃)₂), 22.0 (CH₃ of H₃C₆H₅C(H)(CH₃)₂), 18.8 (CH₃ of H₃C₆H₅C(H)(CH₃)₂).

Synthesis of Ru-para-cymene Cl(C₁₂H₂Cl₂N₂O), 12. Pyridine-2-carboxylic acid (2,5-dichloro-phenyl) amide (0.09 g, 0.32 mmol) was added to a solution of [Ru\{η⁶-para-cymene\}Cl₂]₂ (0.10 g, 0.16 mmol) in
ethanol (50 ml) and the mixture was warmed at 50 °C for 15 minutes then filtered over to ammonium hexafluorophosphate (0.10 g, 0.61 mmol). The resulting solution was stirred overnight then evaporated to dryness. The crude product was washed with petroleum ether (bp 40-60 °C) (3 × 10 ml) and recrystallised from methanol to yield orange crystals of 12 (0.11 g, 0.20 mmol, 62%). ES MS (+): m/z 501 [M']-Cl.

Anal. Found: C 47.3; H 4.5; N 5.0%. Anal. Calc. (with 1 molecule of H2O): C 47.6; H 4.2; N 5.1%. 1H NMR (CD3OD, 500.13MHz, 300K) δ 9.31 (d, 1H, 3J(1'H-1'H)= 5.5 Hz, CH of C6H4N), 8.11 (t of d, 1H, 3J(1'H-1'H)= 7.7 Hz, 4J(1'H-1'H)= 1.4 Hz, CH of C6H4N), 7.96 (d, 1H, 3J(1'H-1'H)= 7.8 Hz, CH of C6H4N), 7.81 (d, 1H, 4J(1'H-1'H)= 2.6 Hz, CH of C6H4Cl), 7.69 (m, 1H, CH of C6H4N), 7.54 (d, 1H, 3J(1'H-1'H)= 8.6 Hz, CH of C6H4Cl), 7.27 (d of d, 1H, 3J(1'H-1'H)= 8.6 Hz, 4J(1'H-1'H)= 2.6 Hz, CH of C6H4Cl), 5.57 (d, 1H, 3J(1'H-1'H)= 5.9 Hz, CH of H3CC6H4CCl(C(H)(CH3))2, 5.48-5.51 (m, 2H, 2 x CH of H3CC6H4CCl(C(H)(CH3))2), 4.94 (d, 1H, 3J(1'H-1'H)= 5.9 Hz, CH of H3CC6H4CCl(C(H)(CH3))2), 2.68 (sept, 1H, 3J(1'H-1'H)= 6.9 Hz, CH of H3CC6H4CCl(C(H)(CH3))2), 2.16 (s, 3H, CH3 of H3CC6H4CCl(C(H)(CH3))2), 1.11 (d, 3H, 3J(1'H-1'H)= 6.9 Hz, CH3 of H3CC6H4CCl(C(H)(CH3))2), 0.00 (d, 3H, 3J(1'H-1'H)= 6.9 Hz, CH3 of H3CC6H4CCl(C(H)(CH3))2); 13C{1H} NMR (CD3OD, 125.77MHZ, 300K) δ 168.6 (CONRu), 155.9 (CH of C6H4N), 155.6 (Quaternary C), 151.8 (Quaternary C), 140.5 (CH of C6H4N), 133.8 (Quaternary C), 131.8 (CH of C6H4Cl), 130.3 (Quaternary C), 128.9 (CH of C6H4Cl), 128.8 (CH of C6H4N), 127.7 (CH of C6H4Cl), 126.6 (CH of C6H4N), 105.5 (Quaternary C of H3CC6H4CCl(C(H)(CH3))2), 98.9 (Quaternary C of H3CC6H4CCl(C(H)(CH3))2), 88.1 (CH of H3CC6H4CCl(C(H)(CH3))2), 86.9 (CH of H3CC6H4CCl(C(H)(CH3))2), 82.2 (CH of H3CC6H4CCl(C(H)(CH3))2), 32.3 (CH of H3CC6H4CCl(C(H)(CH3))2), 22.8 (CH3 of H3CC6H4CCl(C(H)(CH3))2), 21.9 (CH3 of H3CC6H4CCl(C(H)(CH3))2), 18.8 (CH3 of H3CC6H4CCl(C(H)(CH3))2).

Synthesis of Ru-para-cymene Cl(C12H11Cl2N2O), 13. Quinoline-2-carboxylic acid (2,6-dichloro-phenyl)-amide (0.10 g, 0.32 mmol) was added to a solution of [Ru{η⁶-para-cymene}Cl2]2 (0.10 g, 0.16 mmol) in ethanol (50 ml) and the mixture was warmed at 50 °C for 15 minutes then filtered over to ammonium hexafluorophosphate (0.10 g, 0.61 mmol). The resulting solution was stirred overnight then evaporated to dryness. The crude product was washed with petroleum ether (bp 40-60 °C) (3 × 10 ml) and recrystallised
from methanol to yield orange crystals of 15 (0.09 g, 0.15 mmol, 48%). ES MS (+): m/z 551.0 [M+]-Cl.
Anal. Found: C 53.3; H 3.9; N 4.7%. Anal. Calc.:C 53.2; H 4.0; N 4.8%.

1H NMR (CD3OD, 500.13MHz, 300K) δ 8.95 (d, 1H, 3J(H-H) = 8.8 Hz, CH of C6H4N), 8.61 (d, 1H, 3J(H-H) = 8.4 Hz, CH of C6H6N), 8.12-8.14 (m, 2H, 2 x CH of C6H4N), 8.08 (m, 1H, CH of C6H6N), 7.61 (d of d, 1H, 3J(H-H) = 8.0 Hz, 4J(H-H) = 1.4 Hz, CH of C6H3Cl2), 7.29 (t, 1H, 3J(H-H) = 8.1 Hz, CH of C6H3Cl2), 5.79 (m, 2H, 2 x CH of DH2CC6H4C(H)(CH3)2), 5.47 (d, 1H, 3J(H-H) = 6.0 Hz, CH of DH2CC6H4C(H)(CH3)2), 4.87 (d, 1H, 3J(H-H) = 5.5 Hz, CH of DH2CC6H4C(H)(CH3)2), 2.55 (sept, 1H, 3J(H-H) = 6.9 Hz, CH of DH2CC6H4C(H)(CH3)2), 2.17 (s, 2H, CH2D of DH2CC6H4C(H)(CH3)2), 0.99 (d, 3H, 3J(H-H) = 6.9 Hz, CH3 of DH2CC6H4C(H)(CH3)2); 13C {1H} NMR (CD3OD, 125.77MHz, 300K) δ 170.7 (CONRu), 156.6 (Quaternary C), 149.3 (Quaternary C), 148.1 (Quaternary C), 141.4 (CH of C6H6N), 134.5 (Quaternary C), 134.3 (Quaternary C), 132.6 (CH of C6H6N), 132.1 (Quaternary C), 131.0 (CH of C6H6N), 130.8 (CH of C6H5Cl2), 130.1 (CH), 130.0 (CH), 129.9 (CH of C6H6N), 127.9 (CH of C6H5Cl2), 122.8 (CH of C6H6N), 105.1 (C of DH2CC6H4C(H)(CH3)2), 85.5 (CH of DH2CC6H4C(H)(CH3)2), 85.4 (CH of DH2CC6H4C(H)(CH3)2), 85.3 (CH of DH2CC6H4C(H)(CH3)2), 85.0 (CH of DH2CC6H4C(H)(CH3)2), 32.6 (CH of DH2CC6H4C(H)(CH3)2), 23.8 (CH3 of DH2CC6H4C(H)(CH3)2), 21.1 (CH3 of DH2CC6H4C(H)(CH3)2), 19.0 (CH3 of DH2CC6H4C(H)(CH3)2).

ASSOCIATED CONTENT

(Word Style “TE_Supporting_Information”). Supporting Information. CIF files containing crystallographical data for compounds 1, 2, 5, 6, 11 and 12. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

* E-mail: P.C.McGowan@leeds.ac.uk
Author Contributions

All authors have given approval to the final version of the manuscript.

Funding Sources

Technology Strategy Board UK, EPSRC and Ministry of Education, Brunei Darussalam

Notes

The crystal structures were run and solved by Stephanie Lucas.

ACKNOWLEDGMENT

We wish to acknowledge all members of the Technology Strategy Board (TSB) Cp* project along with Technology Strategy Board, EPSRC and Ministry of Education, Brunei Darussalam for funding.

ABBREVIATIONS

Cp*, pentamethylcyclopentadienyl. Cg, centroid.

REFERENCES

Novel rhodium, iridium and ruthenium half-sandwich complexes containing \((N,N)\)-bound picolinamide ligands have been prepared for use as anti-cancer agents. The complexes show promising cytotoxicities, with the presence, position and number of halides having a significant effect on the corresponding IC\(_{50}\) value. A ruthenium complex is more cytotoxic than cisplatin on HT-29 cells and it remains active even under hypoxic conditions making it a promising candidate for in vivo studies.